21 Oct 2021 reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Member news
12 Oct 2021 Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging Member news
12 Oct 2021 Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development Member news
30 Sep 2021 OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
29 Sep 2021 Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC) Member news
22 Sep 2021 Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study Member news
17 Sep 2021 Galapagos announces positive CHMP opinion for Jyseleca® (filgotinib) for the treatment of adults with moderately to severely active ulcerative colitis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
